| Specialty Retail Industry | Consumer Discretionary Sector | Yun Paul Woongsup CEO | KRX SM Exchange | KR7249420001 ISIN |
| South Korea Country | 1,061 Employees | 30 Mar 2026 Last Dividend | 27 Dec 2018 Last Split | - IPO Date |
Ildong Pharmaceutical Co., Ltd., established in 1941, stands as a significant player in the pharmaceutical industry within South Korea. This company focuses on the development, manufacture, and sale of a wide range of pharmaceutical products. It has built a reputation for providing diverse healthcare solutions, including active lactic acid bacterial and anti-diarrheal agents, along with a variety of other pharmaceuticals aimed at treating numerous health conditions. Ildong Pharmaceutical Co., Ltd. not only caters to the domestic market but has also expanded its reach internationally, exporting products to approximately 20 countries worldwide. The company has entered a strategic collaboration with Evotec SE to further enrich its product development capabilities through the INDiGO platform, highlighting its commitment to innovation and global pharmaceutical advancement. The headquarters of Ildong Pharmaceutical Co., Ltd. is located in Seoul, South Korea.
Ildong Pharmaceutical Co., Ltd. offers a broad portfolio of products and services across various therapeutic areas, catering to a wide range of healthcare needs. Some of their offerings include: